We are thrilled to be named IPO/Listing of the Year in the annual European Lifestars Awards. This recognition celebrates our successful Nasdaq #IPO in October 2023, the largest ever of a French-listed #biotech company. Learn more: https://lnkd.in/dAaS8-EF
À propos
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.
- Site web
-
http://www.abivax.com
Lien externe pour Abivax
- Secteur
- Biotechnologie
- Taille de l’entreprise
- 51-200 employés
- Siège social
- Paris, Île-de-France
- Type
- Société cotée en bourse
- Fondée en
- 2013
- Domaines
- R&D, Inflammatory Bowel Desease, Biotechnology, Innovation, Ulcerative colitis et Crohn's disease
Lieux
-
Principal
Obtenir l’itinéraire
7-11, Boulevard Haussmann
75009 Paris, Île-de-France, FR
Employés chez Abivax
Nouvelles
-
Join Abivax at our Symposium “Oral Advanced Therapies in UC: Are more Options Needed?” with Professor Dubinsky & Professor Vermeire on Sunday, October 13th from 10-11am CEST at #UEGWeek 2024.
Sponsored Content Attending #UEGWeek 2024? Check out the Abivax Symposium “Oral Advanced Therapies in UC: Are More Options Needed?” with Prof Dubinsky & Prof Vermeire, 13 October 2024, 10−11 AM CEST. Register here: https://lnkd.in/guMTy-85
-
-
At the core of the science behind Abivax is miR-124, a #microRNA that is well characterized in the scientific literature. miR-124 interacts with specific messenger RNA targets, decreasing their translation into their respective proteins. For more information about our science, visit https://lnkd.in/eKZnghcg.
-
-
Read what Sheldon Sloan, MD, M Bioethics, Abivax Chief Medical Officer had to say about the role of small molecule drugs in #autoimmune and chronic conditions like #ulcerativecolitis with European Pharmaceutical Review:
Learn how Abivax's small molecule treatment could benefit UC patients and why these drugs hold promise to treat autoimmune diseases. #clinicaltrials #smallmolecules #EPRTalks
-
#IBD impacts quality of life for millions worldwide. We are proud to be developing a potential new treatment option for people with chronic inflammatory diseases, like #InflammatoryBowelDisease. Learn more about our commitment to people with IBD: https://lnkd.in/ev-3RDxR #WorldIBDDay
-
-
Tomorrow is #WorldIBDDay. #IBD is a term used to describe conditions characterized by chronic inflammation of the #GI tract, such as ulcerative colitis and Crohn’s disease. Abivax strives to develop therapies to effectively treat inflammatory bowel diseases and improve the lives of people with IBD.
-
-
We are looking forward to attending Digestive Disease Week® (DDW) in Washington, DC. Visit booth 529 to learn more about Abivax and connect with fellow #IBD researchers. #DDW2024
-
-
This #InternationalDayOfFamilies we are highlighting the unique role families play in supporting a loved one or close friend with #IBD. Your support can make a monumental difference in the health and happiness of people living with IBD. Today, we would also like to honor the importance of your dedication and resilience.
-
Pages similaires
Financement
Abivax
6 rounds en tout
Voir plus d’informations sur Crunchbase
Dernier round
Dette après introduction en Bourse
Lien Crunchbase externe pour la dernière levée de fonds
163 465 824,00 $US